Recent News

• 03.27.2025 - Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
• 03.20.2025 - Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
• 02.19.2025 - Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
• 01.27.2025 - Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
• 12.09.2024 - Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
• 12.03.2024 - Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
• 12.03.2024 - Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
• 11.26.2024 - Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
• 11.26.2024 - Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
• 11.19.2024 - Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Recent Filings

• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report
• 01.10.2025 - 8-K Current report
• 11.08.2024 - EX-99.1 EX-99.1
• 11.08.2024 - 8-K Current report
• 11.07.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.07.2024 - 8-K Current report
• 11.07.2024 - EX-99.1 EX-99.1